Imunon Statistics
Total Valuation
Imunon has a market cap or net worth of $7.61 million. The enterprise value is $3.72 million.
| Market Cap | 7.61M |
| Enterprise Value | 3.72M |
Important Dates
The next estimated earnings date is Tuesday, August 4, 2026, before market open.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Imunon has 4.20 million shares outstanding. The number of shares has increased by 145.61% in one year.
| Current Share Class | 4.20M |
| Shares Outstanding | 4.20M |
| Shares Change (YoY) | +145.61% |
| Shares Change (QoQ) | +71.89% |
| Owned by Insiders (%) | 2.03% |
| Owned by Institutions (%) | 5.08% |
| Float | 3.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.01 |
| P/TBV Ratio | 2.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.59, with a Debt / Equity ratio of 0.27.
| Current Ratio | 1.59 |
| Quick Ratio | 1.15 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -768.25% and return on invested capital (ROIC) is -323.04%.
| Return on Equity (ROE) | -768.25% |
| Return on Assets (ROA) | -124.42% |
| Return on Invested Capital (ROIC) | -323.04% |
| Return on Capital Employed (ROCE) | -384.48% |
| Weighted Average Cost of Capital (WACC) | 13.28% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$732,078 |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.94% in the last 52 weeks. The beta is 1.93, so Imunon's price volatility has been higher than the market average.
| Beta (5Y) | 1.93 |
| 52-Week Price Change | -83.94% |
| 50-Day Moving Average | 2.37 |
| 200-Day Moving Average | 3.52 |
| Relative Strength Index (RSI) | 21.41 |
| Average Volume (20 Days) | 69,861 |
Short Selling Information
The latest short interest is 57,617, so 1.37% of the outstanding shares have been sold short.
| Short Interest | 57,617 |
| Short Previous Month | 146,860 |
| Short % of Shares Out | 1.37% |
| Short % of Float | 1.53% |
| Short Ratio (days to cover) | 1.17 |
Income Statement
| Revenue | n/a |
| Gross Profit | -172,216 |
| Operating Income | -14.81M |
| Pretax Income | -14.64M |
| Net Income | -14.64M |
| EBITDA | -14.52M |
| EBIT | -14.81M |
| Earnings Per Share (EPS) | -$4.79 |
Balance Sheet
The company has $4.79 million in cash and $911,752 in debt, with a net cash position of $3.88 million or $0.92 per share.
| Cash & Cash Equivalents | 4.79M |
| Total Debt | 911,752 |
| Net Cash | 3.88M |
| Net Cash Per Share | $0.92 |
| Equity (Book Value) | 3.36M |
| Book Value Per Share | 0.86 |
| Working Capital | 2.45M |
Cash Flow
In the last 12 months, operating cash flow was -$15.03 million and capital expenditures -$20,920, giving a free cash flow of -$15.06 million.
| Operating Cash Flow | -15.03M |
| Capital Expenditures | -20,920 |
| Depreciation & Amortization | 295,227 |
| Net Borrowing | n/a |
| Free Cash Flow | -15.06M |
| FCF Per Share | -$3.58 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Imunon does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -145.61% |
| Shareholder Yield | -145.61% |
| Earnings Yield | -192.49% |
| FCF Yield | -197.94% |
Analyst Forecast
The average price target for Imunon is $17.00, which is 839.23% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.00 |
| Price Target Difference | 839.23% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 7, 2025. It was a forward split with a ratio of 1.15:1.
| Last Split Date | Aug 7, 2025 |
| Split Type | Forward |
| Split Ratio | 1.15:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |